Watch experts decode 'The rise of ESG investing' on October 29 at 4pm. Register Now!
you are here: HomeNewsIndia
Last Updated : Sep 23, 2020 06:33 PM IST | Source: PTI

India launches programme to strengthen clinical trial research capacity of vaccines in neighbouring countries

The first online orientation to this training programme was conducted on September 22 and it was attended by representatives from Nepal, Maldives, Bangladesh, Mauritius, Sri Lanka, Bhutan and Afghanistan.


Amid the COVID-19 pandemic, India has kick-started a "science diplomacy" initiative by launching a programme to strengthen the capacity of clinical trial research of vaccines in neighbouring countries, the Department of Biotechnology said on Wednesday.

The first online orientation to this training programme was conducted on September 22 and it was attended by representatives from Nepal, Maldives, Bangladesh, Mauritius, Sri Lanka, Bhutan and Afghanistan.

"Keeping with the principles outlined by our science diplomacy initiatives, the DBT has initiated the first phase of the training program to strengthen clinical trial research capacity for neighbouring countries’ in partnership with the Ministry of External Affairs,” a statement by the department said.


The training programme which will extend for about six to eight weeks will see participation of investigators, epidemiologists, clinicians and representatives from different departments from Nepal, Maldives, Bangladesh, Mauritius, Sri Lanka, Bhutan and Afghanistan.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

The Department of Biotechnology, through the India Centric Epidemic Preparedness (Ind-CEPI) mission for rapid vaccine development and supporting Indian vaccine development which is aligned with the Global Initiative of the Coalition for Epidemic Preparedness Innovations (CEPI), aims to strengthen the development of vaccines and associated competencies/technologies for the diseases of epidemic potential in India, the statement said.

The objective of these trainings would be to support researchers and investigator teams for enhancing and strengthening their clinical trial capabilities for conducting clinical trials in compliance with International Conference on Harmonisation – Good Clinical Practice (ICH-GCP).

"Through this training programme and knowledge sharing efforts, India is fulfilling its commitment of building various technical capacities in its neighbouring countries. Efforts to network with South Asia, ASEAN and African regions for this purpose would be aided through Ind-CEPI,” the statement said.

Speaking on the occasion, Renu Swarup, Secretary, DBT said building clinical trial capacity in neighbouring countries and all low and middle income countries (LMICs) is a priority for the department.

This initiative is a step in the right direction under the Ind-CEPI mission, Swarup said.

One of the key focus areas of the mission is to support capacity building and regional networking with LMICs, the statement said.

"This will help our participating countries to build capacities for vaccine trials and for conducting Phase-3 trials for COVID-19 vaccines,” it added.

Follow our full coverage of the coronavirus pandemic here.
First Published on Sep 23, 2020 06:33 pm